Anavex Life Sciences
- Anavex Life Sciences 14, Rue Kleberg CH-1201 Geneva, Switzerland
Anavex Life Sciences has announced screening of the first healthy volunteers for the Phase One clinical study of Anavex 2-73, its lead compound for the treatment of Alzheimer's disease.
Anavex Life Sciences has reported promising results from animal studies with Anavex 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.
2 October 2009 - Anavex Life Sciences has selected Forenap Pharma EURL as the contract research organisation for Phase One clinical trials of Anavex 2-73.
Anavex Life Sciences has announced the completion of scale-up manufacturing of Anavex 2-73, its lead compound for the treatment of Alzheimer's disease.
Anavex Life Sciences has published a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the Journal of Pharmacology and Therapeutics.